CureMetrix Announces Agreement with SimonMed Imaging to Improve Care for Patients Nationwide

November 06, 2024 05:00 AM AEDT | By EIN Presswire
 CureMetrix Announces Agreement with SimonMed Imaging to Improve Care for Patients Nationwide
Image source: EIN Presswire

Launching at SimonMed Imaging, AI-powered cmAngio detects breast arterial calcifications, offering enhanced care and a 2-for-1 mammogram. SAN DIEGO, CA, UNITED STATES, November 5, 2024 /EINPresswire.com/ -- CureMetrix®, a leading innovator in AI-driven mammography solutions, proudly announces an agreement with SimonMed Imaging®, one of the largest outpatient medical imaging providers and physician radiology practices in the United States.

Under this agreement, SimonMed Imaging will incorporate CureMetrix's advanced AI-powered imaging solution, cmAngio®, into its network of state-of-the-art facilities nationwide. This integration represents a monumental step in advancing the standard of care in women’s health by leveraging the remarkable capabilities of AI-driven technology.

FDA-cleared cmAngio is an AI-based software that reads mammograms and detects and localizes Breast Arterial Calcifications (BAC). cmAngio analyzes both full-field digital mammography (FFDM) and digital breast tomosynthesis (DBT) screening mammograms to identify and mark these anomalies. It allows radiologists to use existing screening mammograms to identify women who have breast arterial calcifications and as appropriate refer them for additional evaluation.

"We are honored to be working with SimonMed Imaging. Their commitment to women’s health and their leadership in innovative advancements in mammography position them to deliver world-class care for their patients," stated Kevin Harris, President of CureMetrix. "We are extremely pleased to have cmAngio be a part of those efforts and look forward to offering this innovation to their patients.”

The agreement between CureMetrix and SimonMed Imaging underscores their shared commitment to advancing breast health through innovation and AI-driven technology. Together, they are set to transform women's healthcare by delivering more precise, accessible, and affordable care solutions.

"At SimonMed Imaging, our motto 'See Tomorrow Today' reflects our belief that new technology can help provide more accurate diagnoses, but it must also be readily available and affordable to make a real impact," said Dr. John Simon, Chief Executive Officer at SimonMed Imaging. "Our partnership with CureMetrix and the integration of cmAngio is a testament to this mission. By combining innovative tools with the expertise of our subspecialty-trained radiologists, we continue to deliver the highest quality care in a cost-effective and service-oriented environment, empowering better health outcomes for our patients."

SimonMed Imaging is one of the largest outpatient medical imaging providers, with over 200 highly experienced subspecialty-trained radiologists operating across 10 states in over 150 accredited facilities.

"SimonMed Imaging is proud to lead the way in advancing preventive care with cutting-edge imaging technology," said Dr. Sean Raj, Chief Innovation Officer at SimonMed Imaging. "With the introduction of cmAngio, we’re enhancing mammography to provide insights into both breast health and breast arterial calcifications, offering a dual-purpose screening that empowers women with earlier, more comprehensive knowledge of their health while reaffirming our commitment to delivering high-quality, impactful, and affordable care."

For more information about CureMetrix and its innovative women’s health solutions, please visit www.curemetrix.com.

To learn more about SimonMed Imaging, please visit www.simonmed.com.

Brock Anderson
CureMetrix
+1 858-333-5830
[email protected]
Visit us on social media:
Facebook
X
LinkedIn
Instagram

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.